These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 25138550)

  • 1. MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells.
    Shi C; Qi J; Huang P; Jiang M; Zhou Q; Zhou H; Kang H; Qian N; Yang Q; Guo L; Deng L
    Bone; 2014 Nov; 68():67-75. PubMed ID: 25138550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-338-3p inhibits glucocorticoid-induced osteoclast formation through RANKL targeting.
    Zhang XH; Geng GL; Su B; Liang CP; Wang F; Bao JC
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
    Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
    Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
    Idris AI; Landao-Bassonga E; Ralston SH
    Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
    Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action of glucocorticoid on bone-forming and bone-resorbing cells].
    Hakeda Y
    Clin Calcium; 2006 Nov; 16(11):1817-22. PubMed ID: 17079848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
    Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
    Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HtrA1 is upregulated during RANKL-induced osteoclastogenesis, and negatively regulates osteoblast differentiation and BMP2-induced Smad1/5/8, ERK and p38 phosphorylation.
    Wu X; Chim SM; Kuek V; Lim BS; Chow ST; Zhao J; Yang S; Rosen V; Tickner J; Xu J
    FEBS Lett; 2014 Jan; 588(1):143-50. PubMed ID: 24269886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclast differentiation induced by synthetic octacalcium phosphate through receptor activator of NF-kappaB ligand expression in osteoblasts.
    Takami M; Mochizuki A; Yamada A; Tachi K; Zhao B; Miyamoto Y; Anada T; Honda Y; Inoue T; Nakamura M; Suzuki O; Kamijo R
    Tissue Eng Part A; 2009 Dec; 15(12):3991-4000. PubMed ID: 19594360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.
    Martin A; Xiong J; Koromila T; Ji JS; Chang S; Song YS; Miller JL; Han CY; Kostenuik P; Krum SA; Chimge NO; Gabet Y; Frenkel B
    Bone; 2015 Jun; 75():96-104. PubMed ID: 25701138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
    Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
    Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid inhibits cell proliferation in differentiating osteoblasts by microRNA-199a targeting of WNT signaling.
    Shi C; Huang P; Kang H; Hu B; Qi J; Jiang M; Zhou H; Guo L; Deng L
    J Mol Endocrinol; 2015 Jun; 54(3):325-37. PubMed ID: 25878056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-29a protects against glucocorticoid-induced bone loss and fragility in rats by orchestrating bone acquisition and resorption.
    Wang FS; Chuang PC; Lin CL; Chen MW; Ke HJ; Chang YH; Chen YS; Wu SL; Ko JY
    Arthritis Rheum; 2013 Jun; 65(6):1530-40. PubMed ID: 23529662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of glucocorticoids on human osteoclast generation and activity.
    Sivagurunathan S; Muir MM; Brennan TC; Seale JP; Mason RS
    J Bone Miner Res; 2005 Mar; 20(3):390-8. PubMed ID: 15746983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
    Stern PH; Alvares K
    J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.
    Bi Y; Nielsen KL; Kilts TM; Yoon A; A Karsdal M; Wimer HF; Greenfield EM; Heegaard AM; Young MF
    Bone; 2006 Jun; 38(6):778-86. PubMed ID: 16364709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.